Although there were no included studies to detect AD biomarkers by using Simoa assay, fortunately, NDE biomarkers of phosphorylated tau and insulin receptor substrate 1 were validated with Simoa assay in cognitively normal participants who developed AD (Kapogiannis et al., 2019). Here, MAPT is linked to Alzheimer disease.